Excellent announcement today, and great to see the announcements starting to roll in!
I thought I'd run a little exercise and plug those transport/handling and CAPEX savings into our old PFS. This should give us a very conservative NPV estimate for Goulamina (since the PFS was ultra-conservative). Since we have the old values, we should be able to add the present value of the cost savings onto the original NPV values.
For the 1 Mtpa 14 year LOM case:
Annual 6% spodumene exported = 180,000 t (188,000 t from the PFS p.22)
Transport/handling savings = $88/t
Original NPV10 = $85.6 m
PV of cost savings = $3.1 m + $5.0 m + $106.1 m = $114.2 m
New NPV10 = $199.8 m
For the 2 Mtpa 10.3 year LOM case:
Annual 6% spodumene exported = 340,000 t (353,500 t from the PFS p.22)
Original NPV10 = $136.6 m
PV of cost savings = $3.1 m + $5.0 m + $170.2 m = $178.3 m
New NPV10 = $314.6 m
Now this is using the PFS's 6% spod sales price and before taking into account the hefty resource upgrade heading our way!
Happy days
As always, please do your own research.
- Forums
- ASX - By Stock
- FFX
- Ann: Cost Optimisation Delivering Significant Savings - Goulamina
Ann: Cost Optimisation Delivering Significant Savings - Goulamina, page-53
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online